Most Recent
The Commonwealth of Australia is weighing a bid to strike out Otsuka Pharmaceutical's defence as the government seeks lost subsidies after an almost seven-year long patent dispute over the antipsychotic drug, Abilify.
A Federal Court judge has been asked to recuse himself from a legal dispute between Norton Rose Fulbright and a former employment partner who was terminated from the firm.
The Australian Securities and Investments Commission has secured almost $9 million in penalties against Melbourne-based Financial Circle over a scheme to extract advice fees and ongoing commission from borrowers who took out personal loans.
Generic drug maker Alphapharm says rival Sanofi-Aventis waited to amend its injector pen patent until the heated IP battle between the two firms had commenced, despite knowing about the amendments for three years.
A judge has expressed frustration at the slow pace of the Sydney light rail class action, forcing both parties to commit to a timetable that will push the proceeding more rapidly towards a final hearing.
The founder of a fintech company suing Visa for allegedly abusing its market dominance is flying a Federal Court judge to the UK to preside over the examination of a key but reluctant witness in the case, former Visa boss Rupert Keeley.
A judge has approved a $2.5 million penalty against two hearing aid retailers in the consumer regulator's case alleging the companies targeted vulnerable pensioners with misleading newspaper ads.
Judges do not have the power to approve a class action settlement without first issuing an opt-out notice to group members, the court-appointed contradictor in two shareholder class actions against online fashion retailer Surfstitch told the NSW Supreme Court Thursday.
Private education provider Ashley Services may be close to settling a shareholder class action, according to a court order sending the parties in the case to a second mediation session before the end of the year.
Generic Health has shaved two percent off the $25 million damages awarded pharmaceutical giant Bayer in a patent infringement case over Bayer's blockbuster oral contraceptive, Yasmin, but the discount is a far cry from the 15 percent it sought on appeal.